
The flexible dosing schedule has been approved for patients with skin, lung and cervical cancer

This rare, chronic autoimmune disease can cause kidney failure if left untreated

The companies focus on fibrosis and oncology, and novel treatments for respiratory conditions, respectively

Remibrutinib reduced relapse rates and improved disease progression rates

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.